ImageneBio Inc (IMA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$4.17+1.59%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · IMA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 14.3% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| -97.3% |
Growth built into the price is above our model estimate.
The price assumes 111.5 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
IMA — Principal Accounting Officer transition
Dated 2026-06-26
Senior Vice President of Finance and Operations and principal accounting officer — Robert Lally: Mr. Lally resigned and the company plans to search for a replacement.
Why it matters: The company is loss-making and has no product sales listed in these inputs. Higher office and support costs could use cash faster.
Worry ifQ3 G&A expense is above $5.1 million, the reported Q2 2026 level.
Less concerning ifQ3 G&A expense is $5.1 million or less, matching or beating the Q2 2026 level.
Why it matters: The Phase 2b trial is the main test of olevaprubart in atopic dermatitis. Topline data are due in Q4 2027.
Watch forThe November 11 update confirms the trial is on track under the amended plan. Q4 2027 topline timing is unchanged.
Also watch forThe update reports a trial delay, a new protocol change, or topline data moving past Q4 2027.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$157 on $10,000 · ±1.6% | How much price usually moves either way. |
| Bad day | $581 loss on $10,000 · 5.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,354 loss on $10,000 · 53.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.